Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This could be things like insulin resistance, metabolic disorders, eating habits, depressive binge dynamics, and treating those things directly, which we have great confidence, have a meaningful clinical efficacy in helping people not only shed the weight, but also something that's sustainable and something that you can stay on repeatedly for a long period of time |
| Our focus remains on continuing to address barriers that prevent consumers from seeking treatment for specialties that we serve, which we believe will result in greater market share capture |
| So I think really exciting from everything that we're seeing already in the very beginning of the year |
| Growth remains robust as a result of our ability to continue to draw and retain users to the Hims & Hers platform |
| And I think it's giving us, in combination with the more tenured success, a lot of confidence to be able to, at that high end of the range, you know, pull forward of the 2025 guide of $1.2 billion and $100 million in EBITDA a year early |
| We've always taken a disciplined approach to scaling our platform and that is translating to meaningful success on our bottom line as well |
| I'm incredibly proud of our organization's ability to scale our platform efficiently and deliver our first quarter of positive net income on the one-year anniversary of our first quarter of positive adjusted EBITDA |
| But I think instinctively correct, right? I think we're seeing the emerging categories first dermatology, weight loss, show exceptional signs of momentum |
| And so the combination of those things gives us confidence, you know, that retention will continue to improve throughout 2024 |
| What we're excited by in 2024 is that we do see the potential for even higher retention for those users that came on, as well as the existing users that are on the platform just because the products are very uniquely differentiated and they're also at very cost-effective price points |
| It's great that you have the operating leverage to drive towards the long-term margins as you outlined, Yemi |
| In 2023, we made meaningful strides in evolving our platform across a few key dimensions, which has enabled us to capture a leading market share of customers seeking solutions within many of our specialties |
| I think one of the beauties of the overall model is that, you know, given the fact that we have now over 1.5 million subscribers on the platform across many different specialties, we're able to take efficiencies and learnings that we've already historically gotten, and that we also continue to get, you know, with that scale and rapidly deploy them across some of the newer and more emerging offerings |
| Lastly, our operational excellence and scale enable us to offer all of this value to users at attractive price points |
| I think increased confidence in the brand, increased trust in the brand |
| That really enables the ability to drive greater efficiency across the entire ecosystem |
| We are confident that a substantial runway for growth remains, especially as we continue to evolve our offerings |
| And since then have been really refining what we believe is a great clinical offering |
| But we are also pretty excited by the model that we brought to market as a first iteration and plan to continue to expand the portfolio and expand the offering and believe ultimately, this category is going to be a massive contributor to growth |
| As we continue to see increasingly rapid adoption of personalized approaches across newer specialties such as Hers dermatology, mental health and weight loss, we are confident that each of these specialties has the ability to deliver more than $100 million of revenue in 2025 |
| We are pleased to see the strong momentum of the past six years continue into 2024 with continued strength across each of our specialties and margin expansion from our disciplined approach to scale |
| And so I think the rapid adoption of personalized treatment is a really exciting indicator for us of the commitment to the platform and the recommitment of this platform for patients that are in many situations, upselling and adopting the new offerings that are coming on to the platform at a very, very vast market affordable prices |
| It is probably likely going to take us a few years to get there just because in the affiliated pharmacies there are opportunities, both in terms of process, that can drive higher margins as well as, you know, as we look to the scale that we have now, that unlocks the ability to leverage our balance sheet to drive greater efficiencies as well |
| So really excited by both the tenured categories accelerating as a result of the personalization, but also the new emerging categories starting to show some very meaningful contributions to long-term growth |
| And so I think given the size of those markets, which are absolutely enormous, as we know, and the very unique mapped market pricing and personalized approach, it just gives us a tremendous amount of conviction that those emerging categories will be meaningful contributors to growth in the long-term |
| We have high conviction that our strategy of providing users with access to high-quality, personalized solutions that are affordable and backed by an experience that is delightful from beginning to end will position us for continued success in the coming years |
| Over 85% of orders going through affiliated pharmacies provides us greater ability to realize the benefits of scale and ultimately pass value back to consumers in a way that is beneficial for our users and accretive to Hims & Hers |
| Momentum looks to be stronger than ever as we head into 2024 |
| 2023 was an exceptional year for Hims & Hers |
| We are proud of what we are delivering and the positive outcomes we are bringing to our customers, and we are energized by the opportunity we have to bring this incredible experience to an expanding group of consumers in 2024 |
| Statement |
|---|
| And it's not to say that, you know, we're not still excited by the GLP-1 |
| It ticked down a little bit sequentially |
| Because as Yemi said, the holistic offering that patients are getting from access to provider visits constant iteration and treatment, the delivery of the treatment content, that whole thing is really incomparable to a specific drug treatment |
| Mostly on the mental health side, you mentioned that they're seeing a decline in their marketing efficiency and you, obviously, are going to start to see more leverage coming out in 2024 and beyond? So I'm curious if you're seeing a similar degradation in marketing efficiency away from the broad brand building, which it seems like is going to be a majority of your investment in 2024 and beyond |
| These are some of the most emotionally resonant challenges across society today and impact over 100 million individuals in the U.S |
| And obviously, the trial and error that comes with mental health treatment is quite brutal |
| It sounds like some of the initial exuberance around the potential to eventually sell GLP-1s, that sort of died down |
| We've really not seen anything out of the norm, and there's a few reasons, you know, behind that |
| Just curious, in your guidance, how much of new product launches is baked in there, and in your opinion, you know, what could drive potential upside and downside to guidance? Thank you |
Please consider a small donation if you think this website provides you with relevant information